Lead Product(s) : Cannabinol
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InMed Files PCT Patent Application for Neuroprotection in Glaucoma
Details : With INM-088, an eye drop formulation of CBN, the Company is exploring the treatment for glaucoma, either as a prospective stand-alone or an adjunct therapy, and in other ocular diseases.
Product Name : INM-755
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 05, 2020
Lead Product(s) : Cannabinol
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TA-A001
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001
Details : Patent covers the chemical composition of SmartCelle polymers, their method of manufacture and their ability to form 20nm-30nm stable drug-loaded dynamic micelles in aqueous solution. SmartCelle formulations comprising a number of anti-inflammatory drugs...
Product Name : TA-A001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2020
Lead Product(s) : TA-A001
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabinol
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InMed Releases CBN Preclinical Results in Glaucoma
Details : Combination of CBN and elevated pressure, within the same time period, resulted in a high level of cell survival in a dose dependent fashion. CBN was superior to both CBD and THC under identical testing conditions.
Product Name : INM-755
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 27, 2020
Lead Product(s) : Cannabinol
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable